Mr. Davidson is a Managing Director of H.I.G. BioVentures and focuses on investment opportunities in the life sciences sector. Prior to joining H.I.G. in 2004, he was a Vice President with Ventures West with a focus on venture investing in life science companies. Mr. Davidson began his career with Lilly, where he spent a decade in various management roles in the United States and Canada including business development, strategic planning, market research and financial planning. Mr. Davidson currently serves on the boards of Alder Biopharmaceuticals, Inc., Cardeas Pharma, HyperBranch Medical Technology, Intact Vascular, NeurAxon Inc., and Novadaq Technologies. He served on the boards of Salmedix and Gemin X Pharmaceuticals prior to their acquisitions by Cephalon in 2005 and 2011 respectively and the board of Oncogenex Pharmaceuticals prior to their public listing.
Mr. Davidson earned his MBA from Harvard Business School and a Bachelor of Commerce degree from McGill University.
Enoch focuses on investment opportunities in the life sciences sector. Prior to joining H.I.G., he was a Senior Associate at Leerink Partners, a healthcare focused investment bank. Enoch joined Leerink Partners from UBS where he was an Associate Director in the Global Healthcare Investment Banking Group. At Leerink Partners and UBS, Enoch gained extensive experience advising healthcare companies across the biopharmaceutical, medical devices, diagnostics, healthcare services and information technology sectors on equity capital financings, mergers and acquisitions, leveraged buyouts, and recapitalizations.
Some of the transactions Enoch has worked on include the IPOs of Eleven Biotherapeutics and Agios Pharmaceuticals, private placements and follow-on offerings for Kolltan Pharmaceuticals, Intra-Cellular Therapies, Dyax and ProQR Therapeutics, sale of Bravo Health to HealthSpring, sale of WaveMark to Cardinal Health and the leveraged recapitalization of Warner Chilcott Pharmaceuticals.
Previously, Enoch worked in the pharmaceutical industry as a Post-Doctoral Fellow in the R&D Strategy and Analytics group at Bristol-Myers Squibb and as a Pharmacist at CVS Caremark.
Enoch earned an M.B.A. from the Tuck School of Business at Dartmouth and a Doctor of Pharmacy degree from Texas Southern University.
Andrew focuses on investments in therapeutics and medical devices.
Prior to joining H.I.G., Andrew was the Director of Pharmaceutical Sciences at the Clinton Health Access Initiative, where he led several product development programs and managed strategic research collaborations. Andrew began his investment career at Tang Capital Management where he served as a Principal, supporting public and private investments in the biotech space. He later joined Citadel Investment Group's Global Equities team, as a therapeutics and medtech analyst. Previously, Andrew was a Business Development Manager for Genzyme Cardiovascular and helped successfully shepherd a major clinical in-licensing program.
Andrew earned a BSE in Mechanical Engineering from Princeton University, an MD from Harvard Medical School and a PhD in Bioengineering from M.I.T.
Sami Mnaymneh is a Founder and Co-CEO of H.I.G. Capital. He has directed the firm's development since its founding in 1993 and approves all capital commitments made by H.I.G. Sami currently serves on the Board of Columbia College and on the Dean's Council of the Harvard Law School.
Prior to founding H.I.G., Sami was a Managing Director with The Blackstone Group in New York. Prior to that, he was a Vice President in the Mergers and Acquisitions department at Morgan Stanley & Co., where he devoted a significant amount of his time to leveraged buyouts, serving as senior advisor to a number of prominent private equity firms. Over the course of his career, Mr. Mnaymneh has led over 75 transactions in a wide range of industries.
Sami earned a B.A. degree, Summa Cum Laude, from Columbia University where he graduated first in his class, and subsequently received a J.D. degree and an M.B.A. degree, with honors, from Harvard Law School and Harvard Business School, respectively.
As a Managing Director at H.I.G. BioVentures, Bruce focuses on investment opportunities in the life sciences sector, including biopharmaceuticals, medical devices, and diagnostics. Bruce currently serves on the boards of Apollo Endosurgery, CardioFocus, Cerephex, Clarus Therapeutics, Intersection Medical and Iconic Therapeutics.
Bruce has been active in the life sciences sector for more than 20 years. Prior to joining H.I.G., Bruce served most recently as Managing Director at Toucan Capital, an early-stage venture capital fund focusing on life science investments. While at Toucan, Bruce invested in leading drug and device companies throughout the U.S. Prior to Toucan, Bruce was a General Partner at GIV Venture Partners, a venture capital firm focused on early stage investments in the US, India, and China. Prior to his venture capital career, Bruce was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN's partnering and M&A strategies. Bruce started his career as a Research Manager at W.R. Grace & Co., focusing on medical devices.
Bruce is on the boards of the Mid-Atlantic Venture Association, Adventist Healthcare, the University of Delaware Research Foundation, and the BioLife Fund of Virginia’s Center for Innovative Technology. Bruce holds a BSE in Chemical Engineering and BA in Mathematics from the University of Pennsylvania, a PhD in Chemical/Biomedical Engineering from the University of Delaware, and an MBA with High Distinction from Harvard Business School.
Stephanie Stehman is a Vice President at H.I.G. BioVentures and focuses on investment opportunities in the life sciences sector, including diagnostics, therapeutics, and medical devices.
Prior to joining H.I.G., Stephanie was a Senior Consultant with Scisive Consulting, a strategy consulting firm for healthcare businesses. At Scisive, she worked with a range of medical industry clients to provide strategic, financial, and business development support. This work included numerous opportunity assessments and corporate development projects across multiple therapeutic areas. She has extensive experience working within molecular diagnostics, neurology, and the orphan disease space.
Stephanie earned her B.S. in Biology from Muhlenberg College and her Ph.D. in Cell Biology from Columbia University.
Tony Tamer is a Founder and Co-CEO of H.I.G. Capital. He has directed H.I.G.'s development since its founding in 1993 and approves all capital commitments made by the firm. Tony has led a number of successful investments at H.I.G. in both the management buyouts and growth capital arenas. He has extensive experience working with, and coaching, early stage and middle-market companies. Tony is a board member of several H.I.G. portfolio companies. He currently also serves on the Dean's Council of the Harvard University Kennedy School of Government.
Prior to H.I.G., Tony was partner at Bain & Company where he developed business unit and operating strategies, implemented productivity improvement initiatives, and led acquisition and divestiture activities for a number of Fortune 500 clients. Tony has extensive operating experience. He has held marketing, engineering and manufacturing positions at Hewlett-Packard and Sprint Corporation.
Tony holds an M.B.A. degree from Harvard Business School, and a Masters degree in Electrical Engineering from Stanford University. His undergraduate degree is from Rutgers University.
As a Managing Director at H.I.G. BioVentures, Michael Wasserman focuses on investment opportunities in the life sciences sector, including biopharmaceuticals and medical devices. Michael currently represents H.I.G. on the boards of: HyperBranch Medical Technology, Clarus Therapeutics, CardioFocus and NeuWave Medical.
Prior to joining H.I.G., Michael was with Innovations Foundation, where he focused on the creation, financing and development of high technology companies in the life sciences, information technology and engineering sectors. At Innovations Foundation, Michael was instrumental in building multiple high growth companies derived from academic or federally sponsored research programs. Michael has also held prominent operating roles in several entrepreneurial and venture-backed life sciences efforts. Michael was a Founder of CELLutions Biosystems (acquired by Cedarlane Laboratories), where he broadly managed business operations and was directly responsible for the successful negotiation of partnership, co-development and licensing agreements with industry leading pharmaceutical and biotechnology organizations. Michael also has extensive clinical research experience. As Director of Research at Advanced Therapeutics, Michael was involved in a series of seminal clinical studies involving biological approaches to treat rheumatoid arthritis and other autoimmune and inflammatory disorders. Earlier in his career, Michael worked directly for, or as a consultant to, several early stage life sciences businesses, and in the corporate finance, pharmaceutical and clinical research industries.
Michael received his B.Sc. from McGill University and his Ph.D. in Pharmacology from the University of Toronto.